Nilotinib + LDE225
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Conditions
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Trial Timeline
Jan 1, 2012 → Feb 1, 2014
NCT ID
NCT01456676About Nilotinib + LDE225
Nilotinib + LDE225 is a phase 1 stage product being developed by Novartis for Philadelphia Chromosome Positive Chronic Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01456676. Target conditions include Philadelphia Chromosome Positive Chronic Myelogenous Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01456676 | Phase 1 | Completed |
Competing Products
20 competing products in Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 3 | 77 |
| STI571 400 mg + STI571 600 mg | Novartis | Phase 2 | 52 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 52 |
| nilotinib | Novartis | Phase 2 | 52 |
| Asciminib + Nilotinib | Novartis | Phase 3 | 77 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Blinatumomab + Asciminib | Novartis | Phase 1/2 | 41 |
| Asciminib | Novartis | Phase 1 | 33 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 41 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 77 |
| Asciminib | Novartis | Approved | 85 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 51 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 76 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 76 |
| Bosutinib | Pfizer | Phase 1/2 | 40 |
| Bosutinib + Bosutinib | Pfizer | Phase 1 | 32 |